Summary
RHHBY Chart
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Experimental drug, divarasib, showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening.
Roche Holding AG Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MD Michelle Dubey Yousif Capital Management LLC | 52,832 | $2.5M | $2.7M | $199,448.53 | 7.96% |
 Anu Prabhu Altrius Capital Management Inc. | 176,959 | $6.6M | $9.01M | $2.42M | 36.64% |
| CGL Chester Gary Lloyd Coston, McIsaac & Partners | 200 | $7,830 | $10,162 | $2,332 | 29.78% |
 Anita Mauro Patrick Mauro Investment Advisor Inc. | 45,578 | $1.59M | $2.32M | $727,418.61 | 45.8% |
| PDH Patrick D. Hayes Canopy Partners LLC | 7,700 | $277,697.63 | $391,860.7 | $114,163.07 | 41.11% |
Roche Holding AG (RHHBY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Roche Holding AG ever had a stock split?
Roche Holding AG Profile
| Pharmaceuticals Industry | Healthcare Sector | Thomas Schinecker CEO | OTCQX Exchange | 771195104 CUSIP |
| CH Country | 103,249 Employees | 13 Mar 2026 Last Dividend | 27 Feb 2014 Last Split | - IPO Date |
Overview
Roche Holding AG is a globally recognized healthcare company that combines its strengths in both pharmaceuticals and diagnostics. With a rich heritage dating back to 1896, the company has established a significant presence across various continents including Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. Roche is committed to improving health and well-being by providing innovative solutions and cutting-edge products in multiple therapeutic areas and diagnostics. The company's headquarters are strategically located in Basel, Switzerland, ensuring a pivotal role in the global healthcare sector.
Products and Services
Roche Holding AG offers a diverse portfolio of products and services across a broad spectrum of medical needs and diagnostic requirements. The company’s offerings can be categorized into pharmaceutical products and diagnostic solutions.
- Pharmaceutical Products: Roche is a leader in developing and marketing medicines for a wide range of diseases. Their therapeutic areas include:
- Anemia
- Blood and solid tumors
- Dermatology
- Hemophilia
- Inflammatory and autoimmune diseases
- Neurological disorders
- Ophthalmology
- Respiratory disorders
- Transplantation
- Diagnostic Solutions: In addition to pharmaceuticals, Roche provides a comprehensive range of diagnostic tools. The company's diagnostics division offers in vitro diagnostic tests for a variety of health conditions, including but not limited to:
- Cancer
- Diabetes
- Covid-19
- Hepatitis
- Human Papillomavirus (HPV)
Through its relentless pursuit of innovation and its expansive portfolio, Roche Holding AG is at the forefront of shaping the future of healthcare by addressing some of the most challenging medical needs and advancing global health.
